Palivizumab in preemies reduces wheezing, study finds

05/8/2013 | DoctorsLounge.com

Premature babies who were given monoclonal antibody palivizumab to protect against respiratory syncytial virus infection had 61% fewer days of wheezing in the first year of life than the placebo group, Dutch researchers found. They also noted a lower number of infants with recurrent wheeze in the palivizumab group. The study was published in the New England Journal of Medicine.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC